This article has Open Peer Review reports available.
Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology
© Paradis et al; licensee BioMed Central Ltd. 2010
Received: 9 October 2009
Accepted: 1 April 2010
Published: 1 April 2010
The availability of clinically valid biomarkers contribute to improve the diagnosis and clinical management of diseases. A valine-to-phenylalanine substitution at position 617 (V617F) in the Janus kinase 2 (JAK2) gene has been recently associated with key signaling abnormalities in the transduction of haemopoietic growth-factor receptors and is now considered as a useful clinical marker of myeloproliferative neoplasms. Several methods have recently been reported to detect the JAK2 V617F point mutation and show variable sensitivity.
Using the Luminex xMAP technology, we developed a quantitative assay to detect the JAK2V617F variant. The method was based on polymerase chain reaction (PCR) followed by hybridization to specific probes coupled with internally dyed microspheres. The assay comprises 3 steps: genomic DNA extraction, end point PCR reaction, direct hybridization of PCR fragments and quantification. It has been tested with different sources of nucleic acid.
Applied to whole blood samples, this quantitative assay showed a limit of detection of 2%. A highly sensitive allele-specific primer extension reaction performed in parallel allowed to validate the results and to identify the specimens with values below 2%.
Direct hybridization assay using the Luminex xMAP technology allows sensitive quantification of JAK2V617F from blood spots. It is simple and can be easily performed in a clinical setting.
Clonal dysregulation linked to myeloproliferative neoplasms (MPN) arising from acquired mutations in the haematopoietic progenitor cells lead to a wide range of clonal haematological malignant diseases including polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelomonocytic leukemia (CMML), chronic myelogenous leukemia (CML), hypereosinophilic syndrome (HES), and systemic mast cell disease (SMCD). These disorders have been studied at the molecular levels and several of them have been associated with gene mutations resulting in constitutive activation of protein tyrosine kinases [2–4].
Jun activated kinase 2 (JAK2) is a cytoplasmic tyrosine kinase with a key role in signal transduction from multiple haemopoietic growth-factor receptors . JAK2 is activated upon the binding of type 1 cytokine ligands including erythropoietin (EPO), granulocyte macrophage-colony stimulating factor (GM-CSF), and thrombopoietin (TPO) with its receptor. This results in the production of red blood cells, granulocytes/macrophages, and platelets, respectively. Recently, several groups have reported a somatically acquired c.1849G>T point mutation in exon 14 of JAK2 gene (JAK2V617F) . This point mutation results in a Valine to Phenylalanine change at position 617 in the JH2 pseudo-kinase domain and may potentially be responsible for key signaling abnormalities observed in several MPN, including PV, ET and IMF [1, 7–9]. This mutation generates a constitutively active tyrosine kinase that confers growth factor independence through the loss of autoinhibition leading to a constitutive activation and uncontrolled proliferation of haematopoietic cells . The JAK2V617F variant is associated with increase hemoglobin concentration, increase levels of white blood cells, splenomegaly, and increase risk of leukemic transformation. Although detected at very low levels in healthy donors , the reported prevalence of the JAK2V617F mutation in MPN is elevated: 90% in PV, 50% in ET or IMF and less then 20% in atypical CML . Complications linked to MPN include fibrosis, hemorrhage, and thrombosis.
Several methods of detection with a wide range of sensitivity have been published for the quantification of this mutation. These methods include: direct sequencing (DS) or RFLP, pyrosequencing, allele-specific primer extension (ASPE), amplification-refractory mutation sequencing (ARMS), quantitative real time PCR (QRT-PCR) and DNA melting curve analysis [6, 11–14]. The Luminex xMAP technology allows simultaneous detection of up to 100 different analytes in a single reaction vessel . This technique is based on PCR reactions followed by direct hybridization (DH) to probes coupled to internally dyed microspheres. Several clinical applications of this flow cytometry-based genotyping technique have been developed and are used for the detection of human pathogens, HLA typing, multiplex screening of genetic diseases, gene expression profiling, risk assessment, diagnosis or clinical follow-up. In this study, we describe a simple quantitative estimation of the JAK2V617F variant applied to whole blood spots stored on FTA cards with a limit of detection of 2%.
This project is part of a "health technology development and assessment" program in molecular biology conducted with the authorization and support of the Chicoutimi hospital and regional health authorities. Genomic DNA was isolated from 20 mL of cultured HEL 92.1.7 cells (ATCC # TIB-180) grown in RPMI complete growth medium using the QIAGEN blood and cell culture DNA kit 100/G (QIAGEN Inc. Canada). DNA concentration was measured by absorbance at 260 and 280 nm using a spectrophotometer. CEPH (Centre d'Étude du Polymorphisme Humain) DNA was purchased from Coriell Institute (Camden, New Jersey 08103, USA). Genomic DNA was isolated from 2 mm punches of whole blood specimens stored at room temperature on Whatman's FTA paper and processed as previously described . Briefly, a 2 mm punch was submerged in 100 μL of methanol and allowed to evaporate overnight. The next day, 25 μL of sterile water was added and the solution incubated at 99°C for 10 min. Once cooled at room temperature, the heating step was repeated and then the tubes were spun at 3000 × g for 5 minutes. The supernatant containing the genomic DNA was transferred to a clean tube and further used for amplification of the targeted sequence using an end point PCR as well as an allele-specific primer extension (ASPE) reaction.
Endpoint PCR and allele-specific primer extension reactions
Primers and probes used in end point PCR, ASPE and DH reactions.
Coupling the oligonucleotide probes to the microspheres and optimization of the hybridization assays
The wild-type probe was coupled to the carboxylated microspheres (xMAP; Luminex Corp., Austin, TX) bead number 064 (Luminex product number L100-C164-01) and mutated probe (Table 1) was coupled to the carboxylated microspheres bead number 065 (Luminex product number L100-C165-01) as described . Each hybridization reaction comprised 2.5 μL of a 1 in 5 diluted PCR products, 10 μL of TE buffer and 25 μL of 1.5× TMAC buffer containing approximately 1500 of each microspheres. The mixture was incubated at 95°C for 10 minutes followed by incubation at 53°C for 30 minutes. To pellet the microspheres, the reactions were quickly spun at 3000 × g for 5 min at room temperature. The supernatant was then removed and the microspheres resuspended in 75 μL of 1× TMAC hybridization buffer containing 4 μg/mL streptavidin-R-phycoerythrin (Invitrogen cat. # S866). The plate was kept in the dark for 10 min and the beads were analyzed at room temperature for assessment of the internal bead color and R-phycoerythrin reporter fluorescence on a Luminex 100 analyzer with the following settings: 45 seconds-50 μL-100 beads. The median fluorescence intensity (MFI) of at least 100 beads was computed for each bead set in the sample. The probes with a unilinker at the 5'ends were purchased from Integrated DNA Technology Inc. (Coralville, IA). The optimal temperature of hybridization was estimated by performing the hybridization at temperatures ranging from 40°C up to 70°C. The effect of DNA concentration on the kinetic of the hybridization reaction was evaluated by testing 5 μL of the PCR products followed by dilutions down to 1:128 and hybridizing at 53°C. The effect of time on the kinetic of the hybridization reaction was determined by using 2.5 μL of PCR product and incubating at 53°C from 0 to 60 min.
Standard curve and quantitative detection of JAK2
The standard curves were generated using the wild-type allele (CEPH DNA) PCR product and the mutated allele (HEL DNA) PCR product diluted five fold and combined together in order to generate a 0 to 100% range of the wild-type to mutated allelic ratios. For the quantitative detection of JAK2V617F, the specimens PCR products were also diluted five fold and then hybridized to the coupled microspheres as described above. The difference between wild type and mutant probes median fluorescence intensity values were used to generate the standard curve and specimen's profiles.
Specimens, Primers and PCR
The initial step of our procedure was to choose the type of genomic DNA and the DNA purification procedure for our assay. To ensure confidentiality of the donor, an aliquot of 50 μL of fresh blood collected in EDTA-containing vaccutainer tubes was spotted onto an FTA card and identified with a number prior to drying overnight. A single FTA card could contain up to 5 specimens linked to its code bar and was easily stored at room temperature in the dark. A single 2 mm punch was sufficient to provide enough genomic DNA for at least 8 genotyping assays. An additional boiling step was added to the original procedure to improve the efficiency of genomic DNA recovery. The amplification of the JAK2V617F targeted region produced a single band of the expected size (155 bp) as visualized from 2% agarose-gel electrophoresis stained with ethidium bromide (not shown). Primers were selected in regions with no known genetic variants preventing the possibility of an allele drop out phenomenon during amplification of the targeted region. To reach the end point status, 45 cycles proved to be sufficient and safe enough assuming 100% amplification efficiency for each PCR cycle. All reactions reached the end point using the procedure described above. Since the primers represent the limiting factor in our PCR reactions, the amount of DNA fragments generated during PCR was about 800 ng which is in agreement with the amount of primers used.
Determination of the optimal kinetic parameters for direct hybridization
Quantitative and qualitative analysis of JAK2V617F variants
The quantitative detection of the JAK2 variants was performed on specimens whole blood spotted onto FTA cards as described above. The MFI values obtained between the wild-type and mutated probes were subtracted from one another and the differences were used to generate a single bar graph (Fig. 5B). By comparing the delta MFI values obtained from the specimens with those of the standard curve (Fig. 5A), a percentage of mutant allele to wild-type was assessable with an estimated limit of detection of 2%. In order to increase the validity and sensitivity of the test, we combined a qualitative ASPE reaction to all specimens tested. All except one specimen negative for JAK2V617F by direct hybridization were negative by ASPE and all specimens positive for JAK2V617F by direct hybridization were positive by ASPE. In this typical example, specimens number 135 and 138 to 145 where given a negative results (absence of the V617F variant) whereas specimens number 133, 134, 136, 137, 146, 147 and 148 where given a positive results (presence of the V617F variant) with values of 35%, 47%, 3%, 90%, 62%, 55% and 55% mutant, respectively. Specimen 143 negative by DH and positive by ASPE was given a value of bellow 2% mutant.
With a 45 cycles PCR reaction, the ASPE assay had a higher sensitivity than the direct hybridization assay and could theoretically detect 0.1% of mutated cells in a wild-type background or 2 mutated alleles out of 2000 or 1 out of 1000 cells. The ASPE reaction included a 3'phosphate-blocked oligonucleotide corresponding to the wild-type allele . This allowed a reduction of the background that sometime occurred from non-specific amplification reaction. A good and reproducible concordance was obtained between the direct hybridization reactions and the ASPE assays (r = 0.95, p < 0.05). Specimens wild type for the JAK2 alleles fluctuated slightly above the 0% standard control. The few that were positive by ASPE and negative by DH were assigned a value bellow 2% mutant.
Since the first reports in 2005 of the JAK2V617F variant, numerous genotyping techniques have been developed. Its detection has been included as a diagnostic criteria for PV by the World Health Organization. Sensitivities vary between 20% for DNA sequencing all the way down to 0.1% for ASPE. Some of them require exhaustive granulocyte DNA purification steps which is time consuming and sometimes difficult because monocytes, granulocytes and platelets may aggregate . In addition, a recent study  suggests that platelets are better suited for JAK2V617F mutation screening since granulocytes analysis could lead to an underestimation of real carriers. This is also supported by recent studies that detected the JAK2V617F mutation in B- and T-lymphocytes  as well as in NK-cells [21, 22] making the use of whole blood better suited then purified granulocytes, although this mutation has not been found in any lymphoid malignancy . A recent study  comparing whole blood and purified blood granulocytes identified a good correlation between both sampling methods with allelic ratio ~15% higher on average for purified granulocytes. Using only the data from blood cell counts and correcting for the percentage of neutrophils, the percentage of mutated JAK2V617F fitted perfectly the values obtained from purified granulocytes.
In this study, we have developed and evaluated a quantitative assay for the detection of the JAK2V617F variant in the Jun activated kinase 2 gene using the Luminex platform. The Luminex technology offers two distinctive approaches, either the xTAG protocol or the xMAP protocol. The former requires a DNA extraction, end point PCR, an exo-sap treatment, an ASPE reaction followed by an hybridization at 37°C. The later requires a DNA extraction, an end point PCR followed by an hybridization at a specific temperature, in this case, at 53°C. Although the xMAP approach implies the predetermination of the optimal kinetic parameters, it requires less steps to perform. The xMAP technology requires a certain level of experience and technical skills, but is simple, sensitive and applicable at a reasonable cost. As starting material, we choose whole blood spotted onto FTA cards because of the genomic DNA stability, potential pathogen inactivation and ease of storage of the specimens. The methanol-water DNA extraction method proved to be simple and highly reproducible allowing multiple genotyping assays from a single 2 mm punch. The end point PCR amplification of the targeted region is straight forward and easily assessed for efficiency by agarose-gel electrophoresis.
We evaluated the possibility of using whole blood spotted onto FTA cards to detect the JAK2V617F genetic variant because of its numerous advantages including (1) the simplicity of collection of blood sample, (2) room temperature storage conditions without need for refrigeration, (3) pathogen inactivation that could be present in human blood, (4) fast purification of DNA and (5) overall low cost when compared to other DNA storage and purification methodologies. In addition, making use of the methanol-water extraction protocol decreases substantially the number of technical steps, time and costs associated with human genomic DNA isolation that is requires for PCR. In contrast, highly purified DNA is required to perform real time PCR making this approach more labor intensive and at increased costs. We believe that FTA cards are therefore a good and inexpensive way to store blood and test for the presence of the JAK2V617F mutation.
A recent report  on the concordance of various assays designed for the quantitative detection of JAK2V617F concluded that the allelic burden as defined by JAK2V617F/total JAK2 produced similar results with variable sensitivity using a common set of standards. It mentions the importance of using defined accurate standards for calibration. Our standards are composed of a mixture of two PCR products eliminating the effect of JAK2 gene copy number variation reported for the HEL cell line. The PCR fragment produced by CEPH DNA being 100% wild-type and the fragment produced by HEL genomic DNA being 100% mutant, a mixture composed of various amounts of both fragments generates standards that are simple to produce and can be directly compared to the PCR fragments from the submitted specimens. By comparison, later standards were composed of various dilutions of UKE-1 cells (homozygous mutant for JAK2V617F) and normal leukocytes (wild-type JAK2). The linear profile of the standard curve from the supplemental data does suggest that the values measured are accurate. We believe that both types of standards are accurate standards and the user may choose which is more convenient depending on their laboratory settings. We tested the 0%, 1%, 10%, 25%, 50%, 75% and 100% mutant control samples (kindly provided by S. Hermouet) and after appropriate dilutions, got values of 0%, 0%, 6%, 22%, 54%, 90% and 100%, respectively, which is a good concordance between both types of standards (data not shown). Our ASPE reaction gave 100% concordance when these controls were tested for the presence or absence of the mutated targeted sequence (not shown). The ASPE reaction did detect the 1% control sample whereas the Luminex DH assay did not which is in good agreement with our estimated limit of detection of 2%.
Patients with more than 50% of mutated JAK2 allele can harbor homozygote clones [22, 24] and can carry wild-type, heterozygous and homozygous clones making questionable the true meaning of a specific percentage value. Some cells even carry multiple copies of the JAK2 gene originating from genetic duplication and recombination. The estimated percentages of JAK2V617F is therefore a value that must not be considered as an actual number of mutated cells compared to all nucleated cells in a sample but rather a variable number of affected cells. Patients with high percentage of JAK2V617F often carry the mutation in a homozygous state that has a direct effect on the true quantitative allele burden measured from whole blood cells.
Using our end point PCR allows the production of a single fragment for each specimen tested that should theoretically represent a constant final concentration assuming that the end point is reached a few cycles before the end of the amplification reactions. From the estimated 1000 genomes present in a single PCR reaction, we estimated that 35 cycles is sufficient to reach the end point assuming 100% amplification efficiency making 45 cycles sufficient for our assay. The five-fold dilution of the specimen PCR products prior to hybridization was implemented because of the ease of making the standard curve mixtures. This also allowed the use of the standard curve samples for many more genotyping assays. Our assay has the advantages of being simple, sensitive, and requires a single PCR reaction.
Although at very low frequency, other mutations have been reported in JAK2 exon 14 [25, 26]. Those that are of particular interest for us are located within the probes targeted sequences and include C616Y and C618R. Theoretically, a compound heterozygous individual carrying the V617F variant on one allele and either C616Y or C618R on the other allele could not be detected unless different probes were used.
We used a standard end point PCR reaction in parallel with an ASPE reaction under identical amplification conditions to validate our assays. During the PCR reaction, both alleles are amplified using the same primers making the amplification efficiency identical for both alleles and consequently has little or no effect on the initial allelic ratios as reported elsewhere . Since both PCR and ASPE reactions are ran under identical conditions and products visualized by agarose-gel electrophoresis, the results are easily comparable reinforcing the final diagnosis regarding the presence or absence of the JAK2V617F variant especially for patients with values bellow 2%.
Direct hybridization of the Luminex xMAP technology is a simple method taking advantage of the unique properties of DNA to form specific hybrids with its complementary sequences. Under specific hybridization conditions such as temperature, DNA concentration, salt concentration and time, one can discriminate two DNA sequences having a single nucleotide polymorphism. To our knowledge, this is the first report of a quantitative detection of a mutated allele linked to a human disease using this technology. We estimated our threshold of detection to be 2% which is similar to most highly sensitive detection technique reported to date. Furthermore, patients with lower than 2% allele burden of the mutated allele should not be considered positive as healthy patient do carry this mutation at very low copies as previously reported . Increased sensitivity could also lead to false positives.
Other mutations relevant to hematopoietic and myeloid malignancies have been reported  and may be detectable by multiplexed PCR followed by our Luminex assay, although the quantitative nature of multiplexing and using direct hybridization is presently under investigation. The next step would be to add other related mutations to evaluate the possibility of multiplexing our quantitative assay as other mutations in either exon 12, 13 and 15 of JAK2 [27, 28] or other genes  linked to MPN have recently been reported.
Direct hybridization assay using the Luminex xMAP technology allows sensitive quantification of JAK2V617F from blood spots. It is simple and can be easily performed to support the diagnosis or clinical management of myeloproliferative diseases.
We thank Drs Daniel Rivard and Winson Tan for their contribution to the manuscript, Alexandre Tremblay for technical help, Lise Girard for performing the assays and Céline Lefèbvre for helping with the picogreen assays. This work was funded through the Canadian Institute of Health Research (CIHR) grant number CTP82941 to DG.
- Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7 (4): 387-97. 10.1016/j.ccr.2005.03.023.View ArticlePubMedGoogle Scholar
- Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood. 2000, 96 (10): 3343-56.PubMedGoogle Scholar
- Reilly JT: Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev. 2003, 17 (4): 241-8. 10.1016/S0268-960X(03)00024-9.View ArticlePubMedGoogle Scholar
- Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM: After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005, 105 (1): 22-30. 10.1182/blood-2003-11-3896.View ArticlePubMedGoogle Scholar
- Rane SG, Reddy EP: Janus Kinases: components of multiple signaling pathways. Oncogene. 2000, 19: 5662-5679. 10.1038/sj.onc.1203925.View ArticlePubMedGoogle Scholar
- Smith CA, Fan G: The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol. 2008, 39 (6): 795-810. 10.1016/j.humpath.2008.02.004.View ArticlePubMedGoogle Scholar
- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365 (9464): 1054-61.View ArticlePubMedGoogle Scholar
- James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434 (7037): 1144-8. 10.1038/nature03546.View ArticlePubMedGoogle Scholar
- Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352 (17): 1779-90. 10.1056/NEJMoa051113.View ArticlePubMedGoogle Scholar
- Sidon P, El Housni H, Dessars B, Heimann P: The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia. 2006, 20 (9): 1622-10.1038/sj.leu.2404292.View ArticlePubMedGoogle Scholar
- Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S: Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica. 2009, 94 (1): 38-45. 10.3324/haematol.13486.View ArticlePubMedGoogle Scholar
- Steensma DP: JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006, 8 (4): 397-411. 10.2353/jmoldx.2006.060007.View ArticlePubMedPubMed CentralGoogle Scholar
- Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S: Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol Diagn. 2007, 9 (1): 42-6. 10.2353/jmoldx.2007.060083.View ArticlePubMedPubMed CentralGoogle Scholar
- Rapado I, Albizua E, Ayala R, Hernández JA, Garcia-Alonso L, Grande S, Gallardo M, Gilsanz F, Martinez-Lopez J: Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol. 2008, 87 (9): 741-9. 10.1007/s00277-008-0512-x.View ArticlePubMedGoogle Scholar
- Dunbar SA, Jacobson JW: Rapid screening for 31 mutations and polymorphisms in the cystic fibrosis transmembrane conductance regulator gene by Luminex xMAP suspension array. Methods Mol Med. 2005, 114: 147-71.PubMedGoogle Scholar
- Caggana M, Conroy JM, Pass KA: Rapid, efficient method for multiplex amplification from filter paper. Hum Mutat. 1998, 11 (5): 404-9. 10.1002/(SICI)1098-1004(1998)11:5<404::AID-HUMU8>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Dunbar SA: Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta. 2006, 363 (1-2): 71-82. 10.1016/j.cccn.2005.06.023.View ArticlePubMedGoogle Scholar
- Tan AY, Westerman DA, Dobrovic A: A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol. 2007, 127 (6): 977-81. 10.1309/1U61JVXTLPPQ7YP1.View ArticlePubMedGoogle Scholar
- Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N: The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007, 136 (5): 745-51. 10.1111/j.1365-2141.2007.06497.x.View ArticlePubMedGoogle Scholar
- Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N: JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol. 2007, 139 (1): 64-9. 10.1111/j.1365-2141.2007.06755.x.View ArticlePubMedGoogle Scholar
- Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM: B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica. 2007, 92 (2): 258-9. 10.3324/haematol.10527.View ArticlePubMedGoogle Scholar
- Delhommeau F, Dupont S, Tonetti C, Massé A, Godin I, Le Couedic JP, Debili N, Saulnier P, Casadevall N, Vainchenker W, Giraudier S: Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007, 109 (1): 71-7. 10.1182/blood-2006-03-007146.View ArticlePubMedGoogle Scholar
- Hermouet S, Dobo I, Lippert E, Boursier MC, Ergand L, Perrault-Hu F, Pineau D: Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F). Leukemia. 2007, 21 (5): 1128-30.PubMedGoogle Scholar
- Ohyashiki K, Hori K, Makino T, Ohyashiki JH: Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. Cancer Genet Cytogenet. 2007, 179 (1): 19-24. 10.1016/j.cancergencyto.2007.07.008.View ArticlePubMedGoogle Scholar
- Yoo JH, Park TS, Maeng HY, Sun YK, Kim YA, Kie JH, Cho EH, Song J, Lee KA, Suh B, Choi JR: JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature. Cancer Genet Cytogenet. 2009, 189 (1): 43-7. 10.1016/j.cancergencyto.2008.09.010.View ArticlePubMedGoogle Scholar
- Tefferi A: JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma. 2008, 49 (3): 388-97. 10.1080/10428190801895360. ReviewView ArticlePubMedGoogle Scholar
- Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, Albitar M: Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009, 11 (1): 49-53. 10.2353/jmoldx.2009.080114.View ArticlePubMedPubMed CentralGoogle Scholar
- Vainchenker W, Dusa A, Constantinescu SN: JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008, 19 (4): 385-93. 10.1016/j.semcdb.2008.07.002.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/11/54/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.